Skip to main content

Treatment Switch Between a JAK Inhibitor (upadacitinib) and TNF Inhibitor (adalimumab) in Patients with RA

  • Sponsored by AbbVie
Jun 01, 2020 12:00 am

What happens when a patient doesn’t adequately respond to a JAK inhibitor or a TNF inhibitor? This video reviews data from the SELECT-COMPARE study looking at what happens when RA patients who have an insufficient response to a JAK inhibitor (upadacitinib) or TNF inhibitor (adalimumab) switch to the alternate therapy.

Sponsored by AbbVie

Content developed by AbbVie Inc. This content is intended for US/PR Healthcare Professionals. The US Medical Affairs department of AbbVie Inc. is the copyright owner of this presentation and has paid RheumNow to host this content. AbbVie is solely responsible for all written and oral content within this presentation © [2020] AbbVie Inc. All rights reserved. The speaker has received compensation from the US Medical Affairs department of AbbVie Inc. to present this information and is speaking on behalf of AbbVie.